These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24064902)

  • 1. Low intraindividual variability of activated partial thromboplastin time revealed in a population of 10,487 control individuals.
    Ma Y; Huh HJ; Kim SH; Kim HJ
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):746-8. PubMed ID: 24064902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significantly different coagulation factor activities underlying the variability of 'normal' activated partial thromboplastin time.
    Park KJ; Kwon EH; Ma Y; Park IA; Kim SW; Kim SH; Kim HJ
    Blood Coagul Fibrinolysis; 2012 Jan; 23(1):35-8. PubMed ID: 22027757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation and performance characteristics of the Q Hemostasis Analyzer, an automated coagulation analyzer.
    Toulon P; Fischer F; Appert-Flory A; Jambou D
    Thromb Res; 2014 May; 133(5):927-35. PubMed ID: 24650798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of atypical APTT derivative curves on the ACL TOP coagulation analyser.
    Solano C; Zerafa P; Bird R
    Int J Lab Hematol; 2011 Feb; 33(1):67-78. PubMed ID: 20649909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.
    Ten Boekel E; Böck M; Vrielink GJ; Liem R; Hendriks H; de Kieviet W
    Thromb Res; 2007; 121(3):361-7. PubMed ID: 17568658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
    Kitchen S; Woolley A
    Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological variation in tests of hemostasis.
    Banfi G; Del Fabbro M
    Semin Thromb Hemost; 2009 Feb; 35(1):119-26. PubMed ID: 19308900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy.
    Ansell J; Tiarks C; Hirsh J; McGehee W; Adler D; Weibert R
    Am J Clin Pathol; 1991 Feb; 95(2):222-7. PubMed ID: 1992612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of high-concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high-hematocrit value.
    Kanahara M; Kai H; Okamura T; Wada T; Suda K; Imaizumi T; Sagawa K
    Thromb Res; 2008; 121(6):781-5. PubMed ID: 17904620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparability of the results of PT-INR with local MNPT and APTTR with MNAPTT on different coagulation analyzers in China.
    Peng L; Yan C; Wu X; Nie L
    Int J Lab Hematol; 2009 Jun; 31(3):352-8. PubMed ID: 18510575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verifying reference intervals for coagulation tests by using stored data.
    Aral H; Usta M; Cilingirturk AM; Inal BB; Bilgi PT; Guvenen G
    Scand J Clin Lab Invest; 2011 Dec; 71(8):647-52. PubMed ID: 22017165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is duplicate testing for prothrombin time and activated partial thromboplastin time necessary?
    Keshgegian AA; Mann JM; Cooper JH
    Arch Pathol Lab Med; 1986 Jun; 110(6):520-2. PubMed ID: 3754725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QCM-D providing new horizon in the domain of sensitivity range and information for haemostasis of human plasma.
    Hussain M; Northoff H; Gehring FK
    Biosens Bioelectron; 2015 Apr; 66():579-84. PubMed ID: 25530537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
    Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
    Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of reagent batch on activated partial thromboplastin time in canine plasma and use of the ratio system for standardization].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 2002; 115(5-6):225-9. PubMed ID: 12058600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure.
    Stevenson KJ; Easton AC; Curry A; Thomson JM; Poller L
    Thromb Haemost; 1986 Apr; 55(2):250-8. PubMed ID: 3715790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.